Journal of Neuro-Oncology

, Volume 131, Issue 3, pp 525–546 | Cite as

Epidemiology for primary brain tumors: a nationwide population-based study

  • Amélie Darlix
  • Sonia Zouaoui
  • Valérie Rigau
  • Faiza Bessaoud
  • Dominique Figarella-Branger
  • Hélène Mathieu-Daudé
  • Brigitte Trétarre
  • Fabienne Bauchet
  • Hugues Duffau
  • Luc Taillandier
  • Luc Bauchet
Clinical Study

Abstract

Primary central nervous system tumors (PCNST) are rare tumors responsible for high mortality and morbidity. Their epidemiology is poorly known, and clinical data are scarcely analyzed at a national level. In this study, we aimed at providing descriptive epidemiological data and incidence rates for all histological subtypes of PCNST according to the WHO classification. We conducted a nationwide population-based study of all newly diagnosed and histologically confirmed PCNST in France, between 2006 and 2011. A total of 57,816 patients were included: male 46.4%, median age at diagnosis 56 years old (range 0–99). For all newly diagnosed PCNST with histological confirmation the crude incidence rate was 15.5/105 per 100,000 person-years. To enable international comparisons, standardized rates were calculated: 14.1/105 (population of reference: USA), 14.5/105 (population of reference: Europe), and 12.0/105 (population of reference: world). 23.4% of samples were cryopreserved. Resection was performed in 79.1% of cases. Results are detailed (incidence rate, sex ratio, median age at diagnosis, number of cryopreserved samples, and type of surgery) for each of the 143 histological subtypes of PCNST, including all rare tumors. For example, incidence rates (population of reference: USA) were 0.018/105 for anaplastic gangliogliomas, 0.054/105 for malignant meningiomas, and 0.036/105 for hemangiopericytomas. Our study is the first to describe incidence rates and epidemiological data for all histological subtypes of PCNST, including rare tumors, at a national level. Its methodology ensures the exhaustiveness of the data collection for histologically-proven cases. Histological population-based studies have many perspectives in the field of clinical epidemiology and research.

Keywords

Brain tumor Epidemiology Incidence Database Neuro-oncology Neuropathology 

References

  1. 1.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system. IARC, LyonGoogle Scholar
  3. 3.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMedGoogle Scholar
  4. 4.
    Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 17(Suppl 4):iv1–iv62CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U et al (2009) The austrian brain tumour registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol 95(3):401–411CrossRefPubMedGoogle Scholar
  6. 6.
    Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A et al (2011) Descriptive epidemiology of CNS tumors in France: results from the Gironde registry for the period 2000–2007. Neuro Oncol 13(12):1370–1378CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J et al (2012) Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer 48(10):1532–1542CrossRefPubMedGoogle Scholar
  8. 8.
    DeAngelis LM (2001) Brain tumors. N Engl J Med 344(2):114–123CrossRefGoogle Scholar
  9. 9.
    Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Pineros M et al (2014) Cancer incidence in five continents, vol X. IARC, LyonGoogle Scholar
  10. 10.
    Johannesen TB, Angell-Andersen E, Tretli S, Langmark F, Lote K (2004) Trends in incidence of brain and central nervous system tumors in Norway, 1970–1999. Neuroepidemiology 23(3):101–109CrossRefPubMedGoogle Scholar
  11. 11.
    Klaeboe L, Lonn S, Scheie D, Auvinen A, Christensen HC, Feychting M et al (2005) Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968–1997. Int J Cancer 117(6):996–1001CrossRefPubMedGoogle Scholar
  12. 12.
    Deltour I, Johansen C, Auvinen A, Feychting M, Klaeboe L, Schüz J (2009) Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974–2003. J Natl Cancer Inst 101(24):1721–1724CrossRefPubMedGoogle Scholar
  13. 13.
    Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Geraci M et al (2010) Are reported increases in incidence of primary CNS tumours real? An analysis of longitudinal trends in England, 1979–2003. Eur J Cancer 46(9):1607–1616CrossRefPubMedGoogle Scholar
  14. 14.
    Kaatsch P, Rickert CH, Kühl J, Schüz J, Michaelis J (2001) Population-based epidemiologic data on brain tumors in German children. Cancer 92(12):3155–3164CrossRefPubMedGoogle Scholar
  15. 15.
    McCarthy BJ, Shibui S, Kayama T, Miyaoka E, Narita Y, Murakami M et al (2012) Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries. Neuro Oncol 14(9):1194–1200CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Desandes E, Guissou S, Chastagner P, Lacour B (2014) Incidence and survival of children with central nervous system primitive tumors in the french national registry of childhood solid tumors. Neuro Oncol 16(7):975–983CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ruiz-Tovar M, López-Abente G, Pollán M, Aragonés N, Ardanaz E, Moreo P et al (1999) Brain cancer incidence in the province of Zaragoza and Navarre (Spain): effect of age, period and birth cohort. J Neurol Sci 164(1):93–99CrossRefPubMedGoogle Scholar
  18. 18.
    Caldarella A, Crocetti E, Paci E (2011) Is the incidence of brain tumors really increasing? A population-based analysis from a cancer registry. J Neurooncol 104(2):589–594CrossRefPubMedGoogle Scholar
  19. 19.
    Bauchet L, Rigau V, Mathieu-Daudé H, Figarella-Branger D, Hugues D, Palusseau L et al (2007) French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol 84(2):189–199CrossRefPubMedGoogle Scholar
  20. 20.
    Rigau V, Zouaoui S, Mathieu- Daudé H, Darlix A, Maran A, Trétarre B et al (2011) French brain tumor database: 5-year histological results on 25756 cases. Brain Pathol 21(6):633–644CrossRefPubMedGoogle Scholar
  21. 21.
    Zouaoui S, Rigau V, Mathieu-Daudé H, Darlix A, Bessaoud F, Fabbro-Peray P et al (2012) French brain tumor database: general results on 40,000 cases, main current applications and future prospects. Neurochirurgie 58(1):4–13CrossRefPubMedGoogle Scholar
  22. 22.
    Zouaoui S, Darlix A, Rigau V, Mathieu- Daudé H, Bauchet F, Bessaoud F et al (2015) Descriptive epidemiology of 13,038 newly diagnosed and histologically confirmed meningiomas in France: 2006–2010. Neurochirurgie. pii: S0028-3770(15):00073–9.Google Scholar
  23. 23.
    Kleihues P, Cavenee WK (eds) (2000) World health classification of tumors. Tumors of the nervous system. Pathology and genetics. IARC Scientific Publications, LyonGoogle Scholar
  24. 24.
    Dolecek TA, Dressler EV, Thakkar JP, Liu M, Al-Qaisi A, Villano JL (2015) Epidemiology of meningiomas post-Public Law 107–206: The Benign Brain Tumor Cancer Registries Amendment Act. Cancer 121(14):2400–2410CrossRefPubMedGoogle Scholar
  25. 25.
    Ostrom QT, de Blank PM, Kruchko C, Petersen CM, Liao P, Finlay JL et al (2015) Alex’s lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 10):x1–x36CrossRefPubMedGoogle Scholar
  26. 26.
    Selvanathan SK, Hammouche S, Salminen HJ, Jenkinson MD (2011) Outcome and prognostic features in anaplastic ganglioglioma: analysis of cases from the SEER database. J Neurooncol 105(3):539–545CrossRefPubMedGoogle Scholar
  27. 27.
    Couce ME, Aker FV, Scheithauer BW (2000) Chordoid meningioma: a clinicopathologic study of 42 cases. Am J Surg Pathol 24(7):899–905CrossRefPubMedGoogle Scholar
  28. 28.
    Di Ieva A, Laiq S, Nejad R, Schmitz EM, Fathalla H, Karamchandani J et al (2015) Chordoid meningiomas: incidence and clinicopathological features of a case series over 18 years. Neuropathology 35(2):137–147CrossRefPubMedGoogle Scholar
  29. 29.
    Sonabend AM, Zacharia BE, Goldstein H, Bruce SS, Hershman D, Neugut AI et al (2014) The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis. J Neurosurg 120(2):300–308CrossRefPubMedGoogle Scholar
  30. 30.
    Smoll NR, Drummond KJ (2012) The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci 19(11):1541–1544CrossRefPubMedGoogle Scholar
  31. 31.
    Johnston DL, Keene D, Kostova M, Strother D, Lafay-Cousin L, Fryer C et al (2014) Incidence of medulloblastoma in Canadian children. J Neurooncol 120(3):575–579CrossRefPubMedGoogle Scholar
  32. 32.
    Bauchet L, Mathieu-Daudé H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O et al (2010) Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol 12(7):725–735CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Scott JG, Bauchet L, Fraum TJ, Nayak L, Cooper AR, Chao ST et al (2012) Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer 118(22):5595–5600CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Zouaoui S, Darlix A, Fabbro- Peray P, Mathieu-Daudé H, Rigau V, Fabbro M et al (2014) Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. Neurosurg Rev 37(3):415–423CrossRefPubMedGoogle Scholar
  35. 35.
    Darlix A, Zouaoui S, Virion JM, Rigau V, Mathieu-Daudé H, Blonski M et al (2014) Significant heterogeneity in the geographical distribution of diffuse grade II/III gliomas in France. J Neurooncol 120(3):547–555CrossRefPubMedGoogle Scholar
  36. 36.
    Menei P, Figarella-Branger D, Bauchet L, Loiseau H, Denyset M, Roman T et al (2014) French research infrastructures to develop and validate glioma biomarkers. Neurosurgery 75(2):E195–E196CrossRefPubMedGoogle Scholar
  37. 37.
    Labreche K, Simeonova I, Kamoun A, Gleize V, Chubb D, Letouzé E et al (2015) TCF12 is mutated in anaplastic oligodendroglioma. Nat Commun 6:7207CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Amélie Darlix
    • 1
    • 2
  • Sonia Zouaoui
    • 3
    • 4
  • Valérie Rigau
    • 5
  • Faiza Bessaoud
    • 3
  • Dominique Figarella-Branger
    • 6
  • Hélène Mathieu-Daudé
    • 3
  • Brigitte Trétarre
    • 3
  • Fabienne Bauchet
    • 3
  • Hugues Duffau
    • 2
    • 4
  • Luc Taillandier
    • 7
  • Luc Bauchet
    • 2
    • 4
  1. 1.Department of Medical OncologyInstitut Régional du Cancer de Montpellier (ICM)—Val d’AurelleMontpellierFrance
  2. 2.INSERM U1051MontpellierFrance
  3. 3.Department of Epidemiology, French brain tumor database, GNOLR, Registre des Tumeurs de l’HéraultInstitut Régional du Cancer de Montpellier (ICM)—Val d’AurelleMontpellierFrance
  4. 4.Department of NeurosurgeryGui de Chauliac HospitalMontpellierFrance
  5. 5.Department of PathologyGui de Chauliac HospitalMontpellierFrance
  6. 6.Department of Neuropathology and INSERM U911, Timone HospitalUniversité de la MéditerranéeMarseilleFrance
  7. 7.Neuro-oncology UnitUniversity HospitalNancyFrance

Personalised recommendations